Investor Presentaiton

Cardiovascular milvexian Camzyos Our framework reinforces confidence in milvexian as a next-generation anti-thrombotic Transformational potential Oral anti-coagulant with a potential for comparable/better efficacy with reduced bleed risk to a broader range of patients Causal human biology Congenital FXI-deficient patients: • Lower risk for venous thromboembolism & ischemic strokes Spontaneous bleeding is uncommon Risk of CV events lower by¹ 43% Risk of VTE lower by 48% 61% In patients with mild deficiency In patients with moderate-to- HR 0.52 severe deficiency In patients with mild deficiency HR 0.39 HR 0.571 Matching modality to mechanism MYK-224 Milvexian has high affinity and specificity for FXla, high oral bioavailability and demonstrates a wide therapeutic index in preclinical models of thrombosis Path to clinical proof-of-concept Human genetic data Epidemiologic observations No VTE events Pre-clinical models In patients with moderate-to- severe deficiency¹ Phase 2 studies Ill Bristol Myers Squibb™ 1. Preis M, et al. Blood. 2017; Mar;129(9):1210-1215. Not for Product Promotional Use 114

View entire presentation